fC6MQX

Poster Presentations – Monday, October 20, 10:30 am - 4:00 pmP1039. No Increase in Serious or Mild Infectious Complications ofImmunosuppression in an Office-Based IBD Population: A ProspectiveStudyChris Shepela, MD, MS, Justin Howard, MD, Katherine Janssen, MD,Kathleen Barrett, CNP, GI, Health Partners, Saint Paul, MNP1040. Anti-TNF Agents Prevent Endoscopic and Clinical Recurrence ofCrohn’s Disease After Surgical Resection: A Meta-AnalysisHoussam Mardini, MD, MBA, MPH, FACG, Alla Grigorian, MD, PhD,Lisbeth Selby, MD, Terrence Barrett, MD, University of Kentucky,Lexington, KYP1041. Response Rates to Anti-TNF Biologic Therapy After Failure of aPrior Biologic: A Retrospective Analysis of a Single Center’s ExperienceWilliam Ferges, MD, Geoffrey You, MD, Muhammad Shafqet, MD,Qasim Salimi, MD, Daniel Schaer, MD, Eleazer Yousefzadeh, MD, KironDas, MD, PhD, FACG, S. Devi Rampertab, MD, FACG, Rutgers - RobertWood Johnson Medical School, New Brunswick, NJP1042. Side Effect Profiles of Anti-TNF Biologics in the Treatment ofInflammatory Bowel Disease: Experience of a Single Crohn’s and ColitisCenterWilliam Ferges, MD, Qasim Salimi, MD, Geoffrey You, MD, MuhammadShafqet, MD, Daniel Schaer, MD, Kiron Das, MD, PhD, FACG, S. DeviRampertab, MD, FACG, Rutgers - Robert Wood Johnson MedicalSchool, New Brunswick, NJP1043. Clinical Predictors of a Poor Response to Anti-TNF BiologicTherapy for Inflammatory Bowel DiseaseWilliam Ferges, MD, Muhammad Shafqet, MD, Qasim Salimi, MD,Geoffrey You, MD, Daniel Schaer, MD, Kiron Das, MD, PhD, FACG, S.Devi Rampertab, MD, FACG, Rutgers - Robert Wood Johnson MedicalSchool, New Brunswick, NJP1044. Analysis of Risk Factors for Avascular Necrosis in InflammatoryBowel DiseaseSiddhant Yadav, MD, Scott Harmsen, MS, Edakkanambeth VarayilJithinraj, MD, Kevin Karls, MD, William Tremaine, MD, FACG, EdwardLoftus, MD, FACG, Gastroenterology and Hepatology, Mayo Clinic,Rochester, MN, Mid-Dakota Clinic, Bismarck, NDP1045. Incidence and Outcomes of Home Parenteral Nutrition in PatientsWith Crohn’s Disease in Olmsted County, MinnesotaSiddhant Yadav, MD, Edakkanambeth Varayil Jithinraj, MD, ScottHarmsen, MS, William Tremaine, MD, FACG, Ryan Hurt, MD, PhD,Edward Loftus, MD, FACG, Gastroenterology and Hepatology, MayoClinic, Rochester, MNP1046. The C. difficile Relapse Rate Is Low in IBD Patients Who HaveMetronidazole or Vancomycin as Initial TherapyLilani Perera, MD, Amar Dodda, MD, Yelena Zadvornova, Daniel Stein,MD, Amar Naik, MD, Kari Best, PA-C, Kathleen Idstein, PA-C, BensonMassey, MD, Medicine, Medical College of Wisconsin, Milwaukee, WIP1047. Predictors of Satisfaction With Life Among Adult Patients WithEstablished Crohn’s DiseaseOrly Sarid, PhD, Vered Slonim-Navo, PhD, Michael Friger, PhD, HillelVardi, MS, Doron Schwartz, MD, Daniela Munteau, MD, Vitaly Dizengof,MD, Alex Moshkelo, MD, Alex Rozental, MD, Gil Ben Yaakov, MD,Pavel Krugliak, MD, Naim Abu Freha, MD, Leslie Eidelman, MD, NavaGaspar, MD, Alex Fich, MD, Dan Greenberg, PhD, Shmuel Odes, MD,Social Work, Ben-Gurion University of the Negev, Beer Sheva, Israel,Public Health, Ben-Gurion University of the Negev, Beer Sheva, Israel,Gastroenterology and Hepatology, Soroka Medical Center, Beer Sheva,Israel, Health Systems Management, Ben-Gurion University of theNegev, Beer Sheva, Israel, Gastroenterology, Ben-Gurion University ofthe Negev, Beer Sheva, IsraelP1048. Imbalanced Intestinal Microbiota in Treatment-Naïve PatientsWith Inflammatory Bowel Disease by a Metagenomic ApproachYoulian Zhou, MS, Yan He, PhD, Pu Wang, PhD, Ting Zhang, PhD,Jiasheng Tan, MS, Minyi Lin, MS, Yunsheng Yang, PhD, Bo Jiang,PhD, Hongwei Zhou, PhD, Ye Chen, PhD, Gastroenterology.NanfangHospital, Southern Medical University, Guangzhou, China, Departmentof Environmental Health,School of Public Health and Tropical Medicine,Southern Medical University, Guangzhou, China, Institute of DigestiveDiseases, Chinese PLA General Hospital, Beijing, ChinaP1049. SHIELD 4 Phase 3 Clinical Trial With Orally Administered CCR9Inhibitor Vercirnon in Crohn’s DiseaseSatish Keshav, MD, PhD, Thomas Schall, PhD, Pirow Bekker, MD, PhD,John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom,ChemoCentryx, Inc., Mountain View, CAP1050. Predictors of Hospitalization in Patients With Moderately toSeverely Active Ulcerative Colitis From ULTRA 1 and ULTRA 2Brian Feagan, MD, William Sandborn, MD, Walter Reinisch, MD,Subrata Ghosh, MD, Anne Robinson, MD, Andreas Lazar, MD, QianZhou, PhD, Martha Skup, MD, Roopal Thakkar, MD, University ofWestern Ontario, London, ON, Canada, University of California SanDiego, La Jolla, CA, McMaster University, Hamilton, ON, Canada,University of Calgary, Calgary, AB, Canada, AbbVie Inc, NorthChicago, IL, AbbVie Deutschland GmbH and Co. KG, Ludwigshafen,GermanyP1051. Patients With Refractory Crohn’s Disease Successfully TreatedWith UstekinumabKimberly Harris, MD, Sara Horst, MD, Akash Gadani, MD, AnneNohl, PA, Kimberly Annis, PA, Caroline Duley, NP, Dawn Beaulieu,MD, Leyla Ghazi, MD, David Schwartz, MD, Vanderbilt UniversityMedical Center, Nashville, TN, University of Maryland MedicalCenter, Baltimore, MDP1052. Efficacy of High-Dose Versus Low-Dose Methotrexate inCombination Therapy for Inflammatory Bowel DiseaseRuben Colman, MD, David Rubin, MD, FACG, IBD Center, Universityof Chicago Medicine, Chicago, ILP1053. POSTER WITHDRAWNP1054. Effects of Increased Vedolizumab Dosing Frequency on DiseaseActivity in Ulcerative Colitis and Crohn’s DiseaseBruce Sands, MD, FACG, Marla Dubinsky, MD, Séverine Vermeire, MD,PhD, Serap Sankoh, PhD, Maria Rosario, PhD, Catherine Milch, MD,Icahn School of Medicine at Mount Sinai, New York, NY, Cedars-SinaiMedical Center, Los Angeles, CA, University Hospital Gasthuisberg,Leuven, Belgium, Takeda Pharmaceuticals International Co.,Cambridge, MAP1055. Underestimation of Disease Severity in Patients WithInflammatory Bowel Disease by Physicians in Case Study SurveyTauseef Ali, MD, A Burak Ozbay, BPharm, MBA, PhD, Martha Skup,PhD, Song Wang, PhD, Brittany Gentile, PhD, Danielle Cohen, MPH,Roopal Thakkar, MD, Jingdong Chao, PhD, University of Oklahoma,Oklahoma City, OK, AbbVie Inc., North Chicago, IL, ICON Plc, SanFrancisco, CAP1056. Physician Survey to Assess Severity Criteria for Patients WithInflammatory Bowel DiseaseTauseef Ali, MD, Martha Skup, PhD, A Burak Ozbay, BPharm, MBA,PhD, Song Wang, PhD, Brittany Gentile, PhD, Danielle Cohen, MPH,Roopal Thakkar, MD, Jingdong Chao, PhD, University of Oklahoma,Oklahoma, OK, AbbVie Inc., North Chicago, IL, ICON Plc, SanFrancisco, CAP1057. Eating Patterns and Disease Activity in Patients WithInflammatory Bowel DiseaseErsilia DeFilippis, BA, Saniya Tabani, BA, Ryan Warren, BA, ColleenWebb, MS, RD, Priyanka Patel, MS, Fatiha Chabouni, MD, PaulChristos, DrPH, MS, Brian Bosworth, MD, FACG, Ellen Scherl,MD, FACG, Weill Cornell Medical College, New York, NY, New YorkPresbyterian-Weill Cornell Medical Center, New York, NYPOSTERSMONDAY85For more information on ACG 2014 and to register, visit www.acgmeetings.gi.org.